← All Rocket Pharmaceuticals, INC filings

Rocket Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RCKT
Rocket Pharmaceuticals, INC
10-K: Rocket Pharma Realigns Strategy, Resubmits KRESLADI BLA
Rocket Pharmaceuticals announced a strategic corporate reorganization to focus on its AAV cardiovascular gene therapy platform, de-prioritizing other programs, and successfully resubmitted its Biologics License Application for KRESLADI.
NASDAQ
RCKT
Rocket Pharmaceuticals, INC
10-K: Rocket Pharmaceuticals Reports 2024 Financial Results, Provides Business Update
Rocket Pharmaceuticals details its financial performance for 2024 and outlines key advancements in its gene therapy programs.
NASDAQ
RCKT
Rocket Pharmaceuticals, INC
10-K: Rocket Pharmaceuticals 10-K Filing: Gene Therapy Pipeline Advances Amidst Regulatory Hurdles
Rocket Pharmaceuticals' 10-K filing highlights progress in its gene therapy pipeline, including regulatory submissions and clinical trial advancements, while acknowledging financial and operational risks.